<DOC>
	<DOCNO>NCT01798875</DOCNO>
	<brief_summary>In addition chronic anovulation hyperandrogenemia , polycystic ovary syndrome ( PCOS ) also characterize peripheral insulin resistance hyperinsulinaemia , turn lead development diabetes , hypertension , atherosclerosis coronary heart disease . Serum marker inflammation increasingly recognize predictor atherosclerosis cardiovascular risk , chronic low-grade inflammation recently propose play role pathogenesis metabolic syndrome type 2 diabetes mellitus . Therefore , aim present study evaluate effect commonly use non-pharmacologic ( diet lifestyle change ) pharmacologic ( oral contraceptive , metformin , anti-androgens ) treatment strategy classical surrogate cardiovascular risk marker woman PCOS . The study hypothesis commonly use therapy woman PCOS may favorable effect classical surrogate marker cardiovascular risk others may even confer high risk cardiovascular event</brief_summary>
	<brief_title>PCOS , Therapy Markers Cardiovascular Risk</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Cyproterone Acetate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>PCOS diabetes pregnancy contraindication oral contraceptive</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>pcos</keyword>
	<keyword>metformin</keyword>
	<keyword>oral contraception</keyword>
	<keyword>cyproterone acetate</keyword>
</DOC>